Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Patient Characteristics
2.2. Changes in Kidney Function and Its Associated Factors in All Patients (n = 663)
2.2.1. Changes in Kidney Function and Incidence of Renal Function Impairment
2.2.2. Logistic Regression Analysis to Predict a Development of Renal Function Impairment
2.2.3. Linear Regression Analysis to Predict Five-Year eGFR
2.2.4. Logistic Regression Analysis to Predict a Decrease of 10% or More in eGFR
2.3. Changes in Kidney Function and Its Associated Factors in Subgroup (n = 287)
2.3.1. Linear Regression Analysis to Predict Five-Year eGFR
2.3.2. Logistic Regression Analysis to Predict a Decrease of 10% or More in eGFR
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Treatment
4.3. Kidney Function
4.4. Dose-Volume Histogram Data
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hong, S.; Won, Y.-J.; Park, Y.R.; Jung, K.-W.; Kong, H.-J.; Lee, E.S. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. Cancer Res. Treat. 2020, 52, 335–350. [Google Scholar] [CrossRef] [PubMed]
- Guideline Committee of the Korean Gastric Cancer Association. Korean Practice Guideline for Gastric Cancer 2018: An Evidence-based, Multi-disciplinary Approach. J. Gastric Cancer 2019, 19, 1–48. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.; Lim, D.H.; Kim, S.; Park, S.H.; Park, J.O.; Park, Y.S.; Lim, H.Y.; Choi, M.G.; Sohn, T.S.; Noh, J.H.; et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J. Clin. Oncol. 2012, 30, 268–273. [Google Scholar] [CrossRef]
- Yu, J.I.; Lim, D.H.; Lee, J.; Kang, W.K.; Park, S.H.; Park, J.O.; Park, Y.S.; Lim, H.Y.; Kim, S.T.; Lee, S.J.; et al. Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiother. Oncol. 2018, 129, 306–312. [Google Scholar] [CrossRef] [PubMed]
- Haneder, S.; Michaely, H.J.; Schoenberg, S.O.; Konstandin, S.; Schad, L.R.; Siebenlist, K.; Wertz, H.; Wenz, F.; Lohr, F.; Boda-Heggemann, J. Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional 1H-MRI and 23Na-MRI. Strahlenther. Onkol. 2012, 188, 1146–1154. [Google Scholar] [CrossRef]
- Yavas, G.; Elsurer, R.; Yavas, C.; Ata, O. Basal renal function reserve and mean kidney dose predict future radiation-induced kidney injury in stomach cancer patients. Support. Care Cancer 2014, 22, 445–451. [Google Scholar] [CrossRef] [PubMed]
- Trip, A.K.; Nijkamp, J.; van Tinteren, H.; Cats, A.; Boot, H.; Jansen, E.P.; Verheij, M. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiother. Oncol. 2014, 112, 289–294. [Google Scholar] [CrossRef] [PubMed]
- Haneder, S.; Budjan, J.M.; Schoenberg, S.O.; Konstandin, S.; Schad, L.R.; Hofheinz, R.D.; Gramlich, V.; Wenz, F.; Lohr, F.; Boda-Heggemann, J. Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer. Strahlenther. Onkol. 2015, 191, 356–364. [Google Scholar] [CrossRef]
- Kaydıhan, N.; Çepni, K.; Ergen, Ş.A.; Şenocak, M.; Öksüz, D. Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy. Jpn. J. Radiol. 2017, 35, 733–739. [Google Scholar] [CrossRef]
- Cockcroft, D.W.; Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31–41. [Google Scholar] [CrossRef]
- Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F., 3rd; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150, 604–612. [Google Scholar] [CrossRef] [PubMed]
- Shemesh, O.; Golbetz, H.; Kriss, J.P.; Myers, B.D. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985, 28, 830–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Acker, B.A.; Koomen, G.C.; Koopman, M.G.; de Waart, D.R.; Arisz, L. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992, 340, 1326–1329. [Google Scholar] [CrossRef]
- Emami, B.; Lyman, J.; Brown, A.; Coia, L.; Goitein, M.; Munzenrider, J.E.; Shank, B.; Solin, L.J.; Wesson, M. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1991, 21, 109–122. [Google Scholar] [CrossRef]
- Cheng, J.C.; Schultheiss, T.E.; Wong, J.Y.C. Impact of Drug Therapy, Radiation Dose, and Dose Rate on Renal Toxicity Following Bone Marrow Transplantation. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71, 1436–1443. [Google Scholar] [CrossRef]
- Dawson, L.A.; Kavanagh, B.D.; Paulino, A.C.; Das, S.K.; Miften, M.; Li, X.A.; Pan, C.; Ten Haken, R.K.; Schultheiss, T.E. Radiation-associated kidney injury. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, S108–S115. [Google Scholar] [CrossRef]
- Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins 2010, 2, 2490–2518. [Google Scholar] [CrossRef] [Green Version]
- van der Vorst, M.J.D.L.; Neefjes, E.C.W.; Toffoli, E.C.; Oosterling-Jansen, J.E.W.; Vergeer, M.R.; Leemans, C.R.; Kooistra, M.P.; Voortman, J.; Verheul, H.M.W. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer 2019, 19, 1066. [Google Scholar] [CrossRef]
- Lindeman, R.D.; Tobin, J.; Shock, N.W. Longitudinal studies on the rate of decline in renal function with age. J. Am. Geriatr. Soc. 1985, 33, 278–285. [Google Scholar] [CrossRef]
- Lindeman, R.D.; Tobin, J.D.; Shock, N.W. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984, 26, 861–868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Esposito, C.; Plati, A.; Mazzullo, T.; Fasoli, G.; De Mauri, A.; Grosjean, F.; Mangione, F.; Castoldi, F.; Serpieri, N.; Cornacchia, F.; et al. Renal function and functional reserve in healthy elderly individuals. J. Nephrol. 2007, 20, 617–625. [Google Scholar] [PubMed]
- Fliser, D.; Franek, E.; Joest, M.; Block, S.; Mutschler, E.; Ritz, E. Renal function in the elderly: Impact of hypertension and cardiac function. Kidney Int. 1997, 51, 1196–1204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nam, H.; Lim, D.H.; Kim, S.; Kang, W.K.; Sohn, T.S.; Noh, J.H.; Kim, Y.I.; Park, C.H.; Park, C.K.; Ahn, Y.C.; et al. A New Suggestion for the Radiation Target Volume after a Subtotal Gastrectomy in Patients With Stomach Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71, 448–455. [Google Scholar] [CrossRef]
- Schwartz, L.H.; Richaud, J.; Buffat, L.; Touboul, E.; Schlienger, M. Kidney mobility during respiration. Radiother. Oncol. 1994, 32, 84–86. [Google Scholar] [CrossRef]
- Macdonald, J.S.; Smalley, S.R.; Benedetti, J.; Hundahl, S.A.; Estes, N.C.; Stemmermann, G.N.; Haller, D.G.; Ajani, J.A.; Gunderson, L.L.; Jessup, J.M.; et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001, 345, 725–730. [Google Scholar] [CrossRef]
- Sakuramoto, S.; Sasako, M.; Yamaguchi, T.; Kinoshita, T.; Fujii, M.; Nashimoto, A.; Furukawa, H.; Nakajima, T.; Ohashi, Y.; Imamura, H.; et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007, 357, 1810–1820. [Google Scholar] [CrossRef]
Characteristic | All (n = 663) | Five-Year eGFR (mL/min/1.73 m2) | p | |
---|---|---|---|---|
≥60 (n = 650) | <60 (n = 13) | |||
Mean Age (years) | 53.2 ± 10.6 | 53.0 ± 10.6 | 62.8 ± 8.6 | 0.001 a |
Sex | ||||
Male | 414 (62.4%) | 406 (62.5%) | 8 (61.5%) | >0.999 |
Female | 249 (37.6%) | 244 (37.5%) | 5 (38.5%) | |
Hypertension | ||||
Yes | 90 (13.6%) | 84 (12.9%) | 6 (46.2%) | 0.004 a |
No | 573 (86.4%) | 566 (87.1%) | 7 (53.8%) | |
Diabetes | ||||
Yes | 68 (10.3%) | 64 (9.8%) | 4 (30.8%) | 0.036 a |
No | 595 (89.7%) | 586 (90.2%) | 9 (69.2%) | |
Chemotherapy | ||||
5-fluorouracil | 296 (44.6%) | 292 (44.9%) | 4 (30.8%) | 0.312 |
TS-1 | 184 (27.8%) | 181 (27.8%) | 3 (23.1%) | |
XP | 183 (27.6%) | 177 (27.2%) | 6 (46.2%) | |
Cisplatin | ||||
Yes | 183 (27.6%) | 177 (27.2%) | 6 (46.2%) | 0.205 |
No | 480 (72.4%) | 473 (72.8%) | 7 (53.8%) | |
Radiotherapy | ||||
Yes | 389 (58.7%) | 381 (58.6%) | 8 (61.5%) | 0.832 |
No | 274 (41.3%) | 269 (41.4%) | 5 (38.5%) | |
Baseline eGFR (mL/min/1.73 m2) | 93.2 ± 12.4 | 93.6 ± 12.2 | 74.5 ± 11.8 | <0.001 a |
Five-year eGFR (mL/min/1.73 m2) | 88.5 ± 13.3 | 89.3 ± 12.1 | 49.6 ± 10.5 | <0.001 a |
Characteristic | All (n = 663) | Radiotherapy | p | |
---|---|---|---|---|
No (n = 274) | Yes (n = 389) | |||
Mean Age (years) | 53.2 ± 10.6 | 55.7 ± 11.2 | 51.4 ± 9.9 | 0.001 a |
Sex | ||||
Male | 414 (62.4%) | 173 (63.1%) | 241 (62.0%) | 0.756 |
Female | 249 (37.6%) | 101 (36.9%) | 148 (38.0%) | |
Hypertension | ||||
Yes | 90 (13.6%) | 47 (17.2%) | 43 (11.1%) | 0.024 a |
No | 573 (86.4%) | 227 (82.8%) | 346 (88.9%) | |
Diabetes | ||||
Yes | 68 (10.3%) | 39 (14.2%) | 29 (7.5%) | 0.005 a |
No | 595 (89.7%) | 235 (85.8%) | 360 (92.5%) | |
Chemotherapy | ||||
5-fluorouracil | 296 (44.6%) | 9 (3.3%) | 287 (73.8%) | <0.001 a |
TS-1 | 184 (27.8%) | 184 (67.2%) | 0 (0.0%) | |
XP | 183 (27.6%) | 81 (29.6%) | 102 (26.2%) | |
Cisplatin | ||||
Yes | 183 (27.6%) | 81 (29.6%) | 102 (26.2%) | 0.343 |
No | 480 (72.4%) | 193 (70.4%) | 287 (73.8%) | |
Baseline eGFR (mL/min/1.73 m2) | 93.2 ± 12.4 | 92.5 ± 12.3 | 93.8 ± 12.5 | 0.176 |
Five-year eGFR (mL/min/1.73 m2) | 88.5 ± 13.3 | 88.7 ± 12.9 | 88.4 ± 13.6 | 0.294 |
Variable | Unstandardized Coefficients | Standardized Coefficients | p | Collinearity Statistics | |||
---|---|---|---|---|---|---|---|
B | SE | Beta | T | Tolerance | VIF | ||
All patients (n = 663) | |||||||
Constant | 53.959 | 4.900 | 11.285 | <0.001 | |||
Age (continuous) | −0.350 | 0.041 | −0.280 | 16.741 | <0.001 | 0.684 | 1.461 |
Cisplatin (0 = N, 1 = Y) | −2.056 | 0.798 | −0.069 | −8.471 | 0.010 | 0.653 | 1.532 |
Radiotherapy (0 = N, 1 = Y) | −2.628 | 0.737 | −0.098 | −3.568 | <0.001 | 0.953 | 1.049 |
Baseline eGFR (continuous) | 0.576 | 0.034 | 0.540 | −2.578 | <0.001 | 0.986 | 1.014 |
Patients who received radiotherapy and whose DVH data were available (n = 287) | |||||||
Constant | 44.350 | 6.502 | 6.821 | <0.001 | |||
Age (continuous) | −0.277 | 0.060 | −0.204 | −4.584 | <0.001 | 0.732 | 1.365 |
Hypertension (0 = N, 1 = Y) | −4.986 | 1.736 | −0.112 | −2.872 | 0.004 | 0.951 | 1.051 |
Kidney V20Gy (continuous) | −0.209 | 0.083 | −0.098 | −2.525 | 0.012 | 0.963 | 1.038 |
Baseline eGFR (continuous) | 0.665 | 0.047 | 0.630 | 14.133 | <0.001 | 0.730 | 1.371 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Park, J.S.; Yu, J.I.; Lim, D.H.; Nam, H.; Kim, Y.I.; Lee, J.; Kang, W.K.; Park, S.H.; Kim, S.T.; Hong, J.Y.; et al. Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. Cancers 2021, 13, 59. https://doi.org/10.3390/cancers13010059
Park JS, Yu JI, Lim DH, Nam H, Kim YI, Lee J, Kang WK, Park SH, Kim ST, Hong JY, et al. Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. Cancers. 2021; 13(1):59. https://doi.org/10.3390/cancers13010059
Chicago/Turabian StylePark, Jun Su, Jeong Il Yu, Do Hoon Lim, Heerim Nam, Young Il Kim, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Seung Tae Kim, Jung Yong Hong, and et al. 2021. "Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses" Cancers 13, no. 1: 59. https://doi.org/10.3390/cancers13010059
APA StylePark, J. S., Yu, J. I., Lim, D. H., Nam, H., Kim, Y. I., Lee, J., Kang, W. K., Park, S. H., Kim, S. T., Hong, J. Y., Sohn, T. S., Lee, J. H., An, J. Y., Choi, M. G., & Bae, J. M. (2021). Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. Cancers, 13(1), 59. https://doi.org/10.3390/cancers13010059